| 1 | 14:00-14:30 | 专题发言 |
少见突变NSCLC综合治疗及进展 |
|
||||
| 2 | 14:30-15:00 | 专题发言 |
EGFR突变晚期NSCLC耐药后规范治疗概况及进展 |
|
||||
| 1 | 15:05-15:25 | 专题报告 |
EGFR TKI耐药的临床挑战与思考 |
|
||||
| 2 | 15:25-15:55 | 专题发言 |
EGFR突变晚期NSCLC一线规范治疗概况及进展 |
|
||||
| 3 | 15:55-16:15 | 专题报告 |
HER2突变NSCLC诊疗现状与未来展望 |
|
||||
| 1 | 16:20-16:50 | 专题发言 |
I-III期NSCLC靶向规范治疗概况及进展 |
|
||||
| 2 | 16:50-17:10 | 专题报告 |
肺癌靶向治疗前沿进展 |
|
||||
| 1 | 17:15-17:20 | 论文发言 |
PSAT1通过丝氨酸合成通路介导非小细胞肺癌进展及其作为代谢治疗靶点的研究 |
|
||||
| 2 | 17:20-17:25 | 论文发言 |
Tumor-derived GRXL3 primes the osteoclast pre-metastatic niche by bifunctional glutathionylation to promote NSCLC bone metastasis |
|
||||
| 3 | 17:25-17:30 | 论文发言 |
Paris polyphylla inhibits lung adenocarcinoma and tumor-associated neutrophils: Insights from Network Pharmacology, Molecular Docking and Experimental Validation |
|
||||